HB-0028

N/A

Report date: 2022/08/10 20:00:49

Base Information

Drug NameHB-0028
Drug Alias NameHB0028注射液HB-0028
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-TGF-βAnti-Programmed death-ligand 1
TargetsTransforming growth factor betaProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursUterine Cervical Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A